The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
Conditions: Obesity; Diabetes Mellitus, Type 2 Interventions: Drug: Dapagliflozin 10mg; Drug: Exenatide 2 mg [Bydureon]; Drug: Placebo Oral Tablet; Drug: Placebo injection; Drug: Insulin; Drug: Metformin, if taken before Sponsors: Universitätsklinikum Hamburg-Eppendorf; AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Byetta | Dapagliflozin | Eating Disorders & Weight Management | Endocrinology | Fortamet | Forxiga | Insulin | Metformin | Obesity | Research